Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 1303-1308

  Bandello, Francesco ^a   de Benedetto, Umberto ^a   Knutsson, Karl Anders ^a   Parodi, Maurizio Battaglia ^a   Cascavilla, Maria Lucia ^a   Iacono, Pierluigi ^b  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Anti VEGF; Diabetic macular edema; Ranibizumab

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DIABETIC MACULAR EDEMA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; ENDOPHTHALMITIS; EVIDENCE BASED MEDICINE; EYE TOXICITY; HEART INFARCTION; HUMAN; INFLAMMATORY PSEUDOENDOPHTHALMITIS; LASER COAGULATION; LOW DRUG DOSE; MONOTHERAPY; PILOT STUDY; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

EID: 81055144787     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/opth.s17423     Document Type: Review

References (27)

1. Early Treatment Diabetic Retinopathy Study Group. Photocoagulation for diabetic macular edema: ETDRS report no. 4. Int Ophthalmol Clin. 1987;27:265-272.
2. Early Treatment Diabetic Retinopathy Study Group. Photocoagulation for DME: Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol. 1985;103:1796-1806.
3. Bandello F, Parodi MB, Lanzetta P, et al. Diabetic macular edema. Dev Ophthalmol. 2010;47:73-110.
4. ETDRS Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94: 761-774.
5. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
6. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs. 2004;13:1275-1293.
7. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845-848.
8. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
10. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: More than meets the eye. Surv Ophthalmol. 2002; 47 Suppl 2:S253-S262.
11. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113:1706-1712.
12. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol. 2006;142:961-969.
13. Nguyen QD, Shah SM, Heier JS, et al; READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology. 2009;116:2175-2181. e1
14. Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117:2146-2151.
15. Genentech. Two pivotal Phase III Lucentis studies showed patients with diabetic macular edema experienced significant improvements in vision and fewer developed more advanced retinopathy. Available from: http://www.gene.com. Accessed June 28, 2011.
16. Wolf S, Massin P, Bandello F, et al; RESOLVE Study Group. Safety and efficacy of ranibizumab treatment in patients with diabetic macular edema: 12-month results of the RESOLVE Study. Presented at the Association for Research in Vision and Ophthalmology meeting May 3-7, 2009, Fort Lauderdale, FL.
17. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): A 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33:2399-2405.
18. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118: 615-625.
19. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: Preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218-224.
20. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: Two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533-1538.
21. Elman MJ, Aiello LP, Beck RW, et al. Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064-1077.
22. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Diabetic Retinopathy Clinical Research Network. Ophthalmology. 2011;118:609-614.
23. Ozturk BT, Kerimoglu H, Bozkurt B, Okudan S. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J Ocul Pharmacol Ther. 2011;27:373-377.
24. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
25. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
26. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57-65.
27. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham- controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150:315-324.